Molecular Determinants of Sensitivity to Polatuzumab-Vedotin in Diffuse Large B-Cell Lymphoma

被引：0

作者：

Corcoran, Sean R. ^{[1
,2
,3
]}

Choi, Jaewoo ^{[4
]}

Fenner, Rachel E. ^{[1
]}

Yu, Xin ^{[4
]}

Scheich, Sebastian ^{[5
]}

Hsiao, Tony ^{[6
]}

Schevchenko, Galina ^{[1
]}

Morris, Vivian M. ^{[4
]}

Phelan, James D. ^{[4
]}

Papachristou, Evangelia K. ^{[7
]}

Kishore, Kamal ^{[7
]}

D'Santos, Clive S. ^{[8
]}

Ji, Yanlong ^{[9
]}

Pittaluga, Stefania ^{[10
]}

Wright, George ^{[11
]}

Urlaub, Henning ^{[12
]}

Pan, Kuan-Ting ^{[13
]}

Oellerich, Thomas ^{[14
]}

Muppidi, Jagan R. ^{[4
]}

Hodson, Daniel James ^{[15
]}

Staudt, Louis M. ^{[4
]}

机构：

[1] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England

[2] Boston Univ, Chobanian & Avedisian Sch Med, Boston, MA USA

[3] NCI, Lymphoid Malignancies Branch, NIH, Boston, MA USA

[4] NCI, Lymphoid Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD USA

[5] Goethe Univ, Frankfurt, Germany

[6] NCI, NIH, Bethesda, MD USA

[7] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England

[8] Univ Cambridge, Cambridge, England

[9] Max Planck Inst Multidisciplinary Sci, Gottingen, Germany

[10] NCI, Pathol Lab, Ctr Canc Res, Bethesda, MD USA

[11] NCI, Biometr Res Program, Div Canc Treatment & Diag, NIH, Bethesda, MD USA

[12] Max Planck Inst Biophys Chem, Gottingen, Germany

[13] MPI Biophys Chem, Gottingen, Germany

[14] Goethe Univ, Frankfurt, Germany

[15] Univ Cambridge, Wellcome MRC Cambridge Stem Cell Inst, Cambridge, England

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-178059

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Corcoran, Sean R.
Phelan, James D.
Choi, Jaewoo
Shevchenko, Galina
Fenner, Rachel E.
Yu, Xin
Scheich, Sebastian
Hsiao, Tony
Morris, Vivian M.
Papachristou, Evangelia K.
Kishore, Kamal
D'Santos, Clive S.
Ji, Yanlong
Pittaluga, Stefania
Wright, George W.
Urlaub, Henning
Pan, Kuan-Ting
Oellerich, Thomas
Muppidi, Jagan
Hodson, Daniel J.
Staudt, Louis M.
CANCER DISCOVERY, 2024, 14 (09) : 1653 - 1674
[2] Molecular determinants of sensitivity to Polatuzumab-Vedotin
Corcoran, Sean R.
Choi, Jaewoo
Fenner, Rachel E.
Yu, Xin
Scheich, Sebastian
Schevchenko, Galina
Papachristou, Evangelia K.
Morris, Vivian M.
Kishore, Kamal
D'Santos, Clive S.
Pittaluga, Stefania
Wright, George
Muppidi, Jagan
Hodson, Daniel J.
Staudt, Louis M.
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[3] Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Tilly, Herve
Morschhauser, Franck
Sehn, Laurie H.
Friedberg, Jonathan W.
Trneny, M.
Sharman, Jeff P.
Herbaux, Charles
Burke, John M.
Matasar, Matthew
Rai, Shinya
Izutsu, Koji
Mehta-Shah, Neha
Oberic, Lucie
Chauchet, Adrien
Jurczak, Wojciech
Song, Yuqin
Greil, Richard
Mykhalska, Larysa
Bergua-Burgues, Juan M.
Cheung, Matthew C.
Pinto, Antonio
Shin, Ho-Jin
Hapgood, Greg
Munhoz, Eduardo
Abrisqueta, Pau
Gau, Jyh-Pyng
Hirata, Jamie
Jiang, Yanwen
Yan, Mark
Lee, Calvin
Flowers, Christopher R.
Salles, Gilles
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (04): : 351 - 363
[4] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
Dietliker, N.
Kiesel, H.
Mueller, R.
Mueller, A. M.
Manz, M.
Zenz, T.
Rosler, W.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 66 - 67
[5] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Sehn, Laurie H.
Herrera, Alex F.
Flowers, Christopher R.
Kamdar, Manali K.
McMillan, Andrew
Hertzberg, Mark
Assouline, Sarit
Kim, Tae Min
Kim, Won Seog
Ozcan, Muhit
Hirata, Jamie
Penuel, Elicia
Paulson, Joseph N.
Cheng, Ji
Ku, Grace
Matasar, Matthew J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
[6] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
Dietliker, N.
Kiesel, H.
Mueller, R.
Mueller, A. M.
Manz, M. G.
Zenz, T.
Rosler, W.
SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
[7] The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma
Kawasaki, Natsumi
Nishito, Yukari
Yoshimura, Yasushi
Yoshiura, Shigeki
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (02) : 245 - 255
[8] An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma
Walji, Moneeza
Assouline, Sarit
EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (09) : 933 - 942
[9] Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma
Hajime Yasuda
Naoko Kaga
Hikari Taka
Tomonori Ochiai
Tomohito Yamana
Yoshiki Miura
Midori Ishii
Makoto Sasaki
Jun Ando
Miki Ando
Cancer Chemotherapy and Pharmacology, 2024, 93 (3) : 265 - 268
[10] Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Shingleton, Jennifer R.
Dave, Sandeep S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 166 - +

← 1 2 3 4 5 →